Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System) (DESSOLVE-C)
A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent® System) in the Treatment of Patients With Coronary Heart Disease
Sponsor: CCRF Consulting Co., Ltd.
Listed as NCT02448524, this PHASE3 trial focuses on Coronary Heart Disease and remains ongoing. Sponsored by CCRF Consulting Co., Ltd., it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Dec 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CCRF Consulting Co., Ltd.
- Giant Med-Pharma Services Inc.
- Hefei Life Science Medical Instruments Co. Ltd.
- Micell Technologies
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Area of Shenyang, China , Baotou, China , Beijing, China , Changchun, China , Changsha, China , Hangzhou, China , Hohhot, China , Lanzhou, China , Nanchang, China , Shanghai, China and 4 more locations